Nutrient DeficiencyNCT06835738
Implementation of Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Uganda
A study testing Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles, Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle and Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles in people with Nutrient Deficiency, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Uganda.
Trial summary
The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Uganda national health system context to support improved maternal nutrition and birth outcomes. Read more about this study
- Who is it for?
- Ages 0 to 80 yearsHealthy volunteers can take part
- Conditions the study is for
- Nutrient Deficiency
- What is being tested?
- Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles, Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle and Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 4,077 participants
- Where
- 1 siteUganda
- Study dates
- 18 Jun 2025to 31 Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 0 to 80 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Inclusion Criteria for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1)
- ≤24 weeks of amenorrhea/gestation as verified by health professionals
- Attending first ANC visit at government or PNFP health facilities.
- Accepted to take MMS at first ANC visit
Exclusion Criteria for Pregnant women- Enrolled for follow-up throughout pregnancy (sample 1)
- Pregnant women with pre-existing hematological conditions such as sickle cell anemia, thalassemia, hemochromatosis.
- Pregnant women planning to relocate outside the study district during the study period.
Inclusion Criteria for Pregnant women / Women that have recently delivered (single contact) (sample 2)
- Currently pregnant woman or a woman who is not more than 8 weeks postpartum.
- Received MMS at an ANC visit at least 3 months ago or more.
- Attended at least any 2 monthly ANC visits.
- Attending/attended ANC at government or private-not-for-profit health facility.
Exclusion Criteria for Pregnant women / Women that have recently delivered (single contact) (sample 2)
- Enrolled in study population 1.
- Women who are more than 8 weeks postpartum.
Inclusion Criteria for ANC providers having ANC health education/counseling with pregnant woman(en) observed (sample 3)
- Healthcare providers that are currently providing ANC health education (group) or ANC individual counseling at government or PNFP health facilities.
Exclusion Criteria for ANC providers having ANC health education/counseling with pregnant woman(en) observed (sample 3) • Healthcare providers that are currently providing ANC health education (group) or ANC individual counseling to a woman(en) that have not provided written informed consent to have the ANC session observed.
Inclusion Criteria for Influential family members (male partners \& mothers/mothers-in law) (sample 4)
- Spouse or partner of a pregnant woman or woman with a child less than 8 weeks old who is receiving/ has received ANC services in one of the 8 study districts.
- Mother or mother-in-law of a pregnant woman or woman with a child less than 8 weeks old who is receiving/ has received ANC services in one of the 8 study districts.
Exclusion Criteria for Influential family members (male partners \& mothers/mothers-in law) (sample 4) • None
Inclusion Criteria for Healthcare Providers- including facility in-charge, ANC providers, Health Assistants, staff in-charge of records, and stores manager (sample 5)
- Health workers who provide ANC services (e.g., midwives/nurse, medical/ clinical officers, health assistants, and nutrition focal person) at government or private-not-for-profit facilities in one of the 8 study districts.
- Health facility staff (e.g., Facility In-charge, Maternity In-charge, Pharmacy/Stores In-charge) at government or private-not-for-profit facilities in one of the 8 study districts.
Exclusion Criteria for Healthcare Providers- including facility in-charge, ANC providers, Health Assistants, staff in-charge of records, and stores manager (sample 5)
- None
Inclusion Criteria for Community Health Workers (VHTs) and Mentor Mothers (sample 6) • Voluntary Health Team (VHT), Mentor Mothers, or Para-socials attached to at least one of the study facilities.
Exclusion Criteria for Community Health Workers (VHTs) and Mentor Mothers (sample 6) • None
Inclusion Criteria for National, regional, and district-level stakeholders (sample 7)
- National, regional, or district-level decision-makers working in nutrition, maternal, newborn and child health, district health educator or pharmaceutical roles associated with the antenatal care system in Uganda.
- Implementing partners involved in direct implementation of MMS within the 8 study districts
Exclusion Criteria for National, regional, and district-level stakeholders (sample 7)
- None
Inclusion Criteria for Pregnant women - interviewed during post-intervention Household Coverage Survey (sample 8)
- Woman who has been pregnant or delivered within the study period.
- Household is within one of the 4 selected districts.
Exclusion Criteria for Pregnant women - interviewed during post-intervention Household Coverage Survey (sample 8)
- Women who moved to the district after delivery.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
About this study
The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Uganda national health system context to support improved maternal nutrition and birth outcomes. Formative research has been conducted to design the implementation strategies that will be tested in this second phase of the study. The objectives are to:
- Describe the implementation of the MMS intervention (which consists of MMS product, a social behavior change communication (SBCC) strategy, capacity building, MMS supply chain support, monitoring, and evaluation) and explore acceptability, feasibility, fidelity, coverage, and potential for sustainability.
- Determine the effect of dispensing MMS in different bottle counts on MMS adherence and ANC attendance among pregnant women.
- Determine the cost and budget impact of MMS intervention implementation integrated in the Ugandan ANC service delivery system
Read the detailed description
Within the context of the existing antenatal care system, investigators will utilize qualitative and quantitative methods to answer the following research questions:
- What is the acceptability, feasibility, fidelity, coverage, and potential for sustainability of an MMS intervention that includes MMS product, a contextualized social behavior change communication (SBCC) plan, capacity strengthening, and modified recording and reporting).
- Does the number of MMS pills in a bottle affect/influence adherence to MMS and/or attendance at ANC attend (30 count bottle vs 90 count bottle vs 180-count bottle).
- What is the cost and budget impact of implementing MMS intervention within the antenatal care (ANC( service delivery system in Uganda.
This is a 3-arm quasi-experimental implementation research (IR) study utilizing a mixed methods data collection approach across multiple study populations (e.g., national, regional, and district-level decision makers, healthcare providers, pregnant women, and other community members). The three study arms are: Study Arm #1 (MMS 180-count), Study Arm #2 (MMS 30-count) and Study Arm #3 (MMS 90-count).
The IR will be conducted in 8 districts representing the South Central, Acholi, and Karamoja regions of Uganda. Sufficient MMS will be provided to the 8 districts to ensure full implementation of MMS across all government (public) facilities and private not-for-profit (PNFP) facilities within the 8 study districts. In other words, all pregnant women who attend ANC through either a public or PNFP health facility within the 8 study districts will be offered MMS rather than IFA.
Each district will be assigned to receive a specific "bottle-count" to be provided to all pregnant women attending ANC in that district. All women will be provided with 180 tablets of MMS delivered in the "bottle-count" option assigned to the district where she is seeking services. The 3 "bottle-count" options are: 1) 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; 2) 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy; or 3) 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). All pregnant women who are assigned to a 30 or 90 bottle count will continue with that bottle count throughout the women's life of pregnancy and postpartum period.
Each "bottle-count" equates to a study arm. Each of the 3 study regions will have slightly different study arms. The districts/study arms within each region were purposively selected under the formative (phase I) of the study. Because there are 3 districts in both the South-Central Region and the Acholi region, each of the 3 districts will serve as a study arm representing one of the three "bottle-count" options. Because there are only 2 districts in the Karamoja region, there will not be a 90-count study-arm.
The study will undertake data collection at approximately 6 facilities per district, representative of the total number of facilities in the districts. Facilities will be purposively selected after being stratified based on the level of the health facility (health center II, health center III, health center IV, or hospital), ownership (government or PNFP), and geographic location.
- Conditions
- Nutrient Deficiency
- Being tested
- Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles, Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle, Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottlesDietary supplement
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottleDietary supplement
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottlesDietary supplement
MMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar.
| Study group | Role | What they receive |
|---|---|---|
| Enhanced MMS delivery with six 30-count bottles (standard packaging amount for IFA) | Active comparator | Pregnant women are provided with six 30-count bottles of MMS monthly during pregnancy, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within each of the 3 study regions). Receives: Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles |
| Enhanced MMS delivery with one 180-count bottle | Active comparator | Pregnant women are provided with one 180-count bottle of MMS at the first ANC visit, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within each of the 3 study regions). Receives: Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle |
| Enhanced MMS delivery with two 90-count bottles | Active comparator | Pregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within 2 of the study regions (e.g., 2 districts). Receives: Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles |
What is being measured
The primary outcome is the main question the study is designed to answer.
MMS Adherence (amount) as assessed by number of MMS tablets consumed
The number of MMS tablets (from a total possible 180 tablets) a pregnant woman consumes (sample 1).
Measured: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
MMS Adherence (frequency) as assessed by the frequency of tablets consumed
The frequency of which MMS tablets are consumed by a pregnant woman. (sample group 1)
Measured: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
ANC Adherence as assessed by the number of ANC visits throughout pregnancy
The number of ANC visits (from a total possible of 8 visits) a pregnant woman makes throughout her pregnancy (sample 1)
Measured: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
Secondary outcomes (3)
Proportion of pregnant women who indicate MMS Acceptability
The proportion of pregnant women (sample group 1 and 2) who agree with domain-specific statements which reflect different aspects of MMS acceptability (MMS packaging, MMS physical properties, MMS side effects, and MMS counseling using The Theoretical Framework of Acceptability uses a 5-point Likert scale where 5 is "strongly agree" and 1 is "strongly disagree". Score range 5-35, a higher score reflects higher acceptability.
Measured: 3-month post-enrolment visit, 6-month post-enrolment visit, 6-week postpartum visit
MMS Acceptability among Health Providers assessed by focus group discussions
Healthcare provider acceptability of MMS across multiple domains (e.g., feasibility of delivering counseling and packaging, time burden) (sample group 5). Measured via focus group discussions at two time points during the study (middle and end).
Measured: 6 months, 12 months
Fidelity of providing MMS among Health Providers as assessed by focus group discussions
Administration of an observation checklist (sample group 3) and a Healthcare Provider Survey (sample 5) at 4 time points during the study
Measured: 3-months, 6-months, 9-months, and 12-months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted19 Feb 2025
- Study start18 Jun 2025
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Nutrient DeficiencyStudies of the same condition, open and under way.
- More trials run by Johns Hopkins Bloomberg School of Public HealthThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- MMS will be implemented across 8 districts in Uganda within 3 regions of Uganda. Two regions have 3 study districts/arms and one region (Karamoja) has two study districts/arms. Study arms/districts have been purposively selected. * Study Arm 1 (3 districts): Provision of 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). along with the novel "job aid/adherence calendar" * Study Arm 2 (3 districts): Provision of 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; along with the novel "job aid/adherence calendar" * Study Arm 3 (2 districts): Provision of 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy along with the novel "job aid/adherence calendar"
- Masking
- None (open label)
- Enrolment
- 4,077 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Johns Hopkins Bloomberg School of Public Health
- Sponsor type
- University, hospital or other
- Collaborators
- Vitamin Angels, UNICEF, Child and Family Foundation of Uganda, Kirk Humanitarian
- Responsible party
- Sponsor
- Investigators
- Monica Fox, MHS, Principal investigator, Johns Hopkins University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06835738
- Sponsor's protocol ID
- IRB00022536/MOD5681
- Status last verified
- Sep 2026
- First submitted
- 14 Feb 2025
- Last updated
- 24 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 24 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Implementation of Multiple Micronutrient Supplementation (MMS) for Pregnant Women in Uganda
- ClinicalTrials.gov ID
- NCT06835738
- Acronym / sponsor ID
- IRB00022536/MOD5681
- Conditions
- Nutrient Deficiency
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 4,077 participants (estimated)
- Lead sponsor
- Johns Hopkins Bloomberg School of Public HealthUniversity, hospital or other
- Collaborators
- Vitamin Angels, UNICEF, Child and Family Foundation of Uganda, Kirk Humanitarian
- Study start
- 18 Jun 2025 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2026 (estimated)
- First posted
- 19 Feb 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective of this research is to understand how antenatal multiple micronutrient supplements (MMS) can be effectively implemented and scaled within the Uganda national health system context to support improved maternal nutrition and birth outcomes. Formative research has been conducted to design the implementation strategies that will be tested in this second phase of the study. The objectives are to:
- Describe the implementation of the MMS intervention (which consists of MMS product, a social behavior change communication (SBCC) strategy, capacity building, MMS supply chain support, monitoring, and evaluation) and explore acceptability, feasibility, fidelity, coverage, and potential for sustainability.
- Determine the effect of dispensing MMS in different bottle counts on MMS adherence and ANC attendance among pregnant women.
- Determine the cost and budget impact of MMS intervention implementation integrated in the Ugandan ANC service delivery system
Detailed description
Within the context of the existing antenatal care system, investigators will utilize qualitative and quantitative methods to answer the following research questions:
- What is the acceptability, feasibility, fidelity, coverage, and potential for sustainability of an MMS intervention that includes MMS product, a contextualized social behavior change communication (SBCC) plan, capacity strengthening, and modified recording and reporting).
- Does the number of MMS pills in a bottle affect/influence adherence to MMS and/or attendance at ANC attend (30 count bottle vs 90 count bottle vs 180-count bottle).
- What is the cost and budget impact of implementing MMS intervention within the antenatal care (ANC( service delivery system in Uganda.
This is a 3-arm quasi-experimental implementation research (IR) study utilizing a mixed methods data collection approach across multiple study populations (e.g., national, regional, and district-level decision makers, healthcare providers, pregnant women, and other community members). The three study arms are: Study Arm #1 (MMS 180-count), Study Arm #2 (MMS 30-count) and Study Arm #3 (MMS 90-count).
The IR will be conducted in 8 districts representing the South Central, Acholi, and Karamoja regions of Uganda. Sufficient MMS will be provided to the 8 districts to ensure full implementation of MMS across all government (public) facilities and private not-for-profit (PNFP) facilities within the 8 study districts. In other words, all pregnant women who attend ANC through either a public or PNFP health facility within the 8 study districts will be offered MMS rather than IFA.
Each district will be assigned to receive a specific "bottle-count" to be provided to all pregnant women attending ANC in that district. All women will be provided with 180 tablets of MMS delivered in the "bottle-count" option assigned to the district where she is seeking services. The 3 "bottle-count" options are: 1) 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; 2) 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy; or 3) 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). All pregnant women who are assigned to a 30 or 90 bottle count will continue with that bottle count throughout the women's life of pregnancy and postpartum period.
Each "bottle-count" equates to a study arm. Each of the 3 study regions will have slightly different study arms. The districts/study arms within each region were purposively selected under the formative (phase I) of the study. Because there are 3 districts in both the South-Central Region and the Acholi region, each of the 3 districts will serve as a study arm representing one of the three "bottle-count" options. Because there are only 2 districts in the Karamoja region, there will not be a 90-count study-arm.
The study will undertake data collection at approximately 6 facilities per district, representative of the total number of facilities in the districts. Facilities will be purposively selected after being stratified based on the level of the health facility (health center II, health center III, health center IV, or hospital), ownership (government or PNFP), and geographic location.
Study design
- Primary purpose
- Health services research
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 3
- Model description
- MMS will be implemented across 8 districts in Uganda within 3 regions of Uganda. Two regions have 3 study districts/arms and one region (Karamoja) has two study districts/arms. Study arms/districts have been purposively selected. * Study Arm 1 (3 districts): Provision of 6 bottles each containing 30 tablets of MMS dispensed monthly over the course of a woman's pregnancy). along with the novel "job aid/adherence calendar" * Study Arm 2 (3 districts): Provision of 1 bottle containing 180 tablets dispensed to the pregnant woman attending the first ANC visit; along with the novel "job aid/adherence calendar" * Study Arm 3 (2 districts): Provision of 2 bottles each containing 90 tablets of MMS dispensed at two different time points during pregnancy along with the novel "job aid/adherence calendar"
| Arm | Type | Receives |
|---|---|---|
| Enhanced MMS delivery with six 30-count bottles (standard packaging amount for IFA) | Active comparator | Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottlesPregnant women are provided with six 30-count bottles of MMS monthly during pregnancy, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within each of the 3 study regions). |
| Enhanced MMS delivery with one 180-count bottle | Active comparator | Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottlePregnant women are provided with one 180-count bottle of MMS at the first ANC visit, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within each of the 3 study regions). |
| Enhanced MMS delivery with two 90-count bottles | Active comparator | Dietary Supplement: Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottlesPregnant women are provided with two 90-count bottles of MMS at two different time points during pregnancy, along with the novel job aid/adherence calendar and associated enhanced MMS counseling (1 district within 2 of the study regions (e.g., 2 districts). |
Who may qualify
- Ages
- 0 to 80 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottlesMMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar. | Dietary supplement | Enhanced MMS delivery with six 30-count bottles (standard packaging amount for IFA) |
| Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottleMMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar. | Dietary supplement | Enhanced MMS delivery with one 180-count bottle |
| Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottlesMMS is a daily supplement provided to pregnant women. It will be delivered to pregnant women through the specified bottle-count protocol as designated by the 3 study arms. ANC providers will be trained to counsel pregnant women on using MMS using a novel job aid/adherence calendar. | Dietary supplement | Enhanced MMS delivery with two 90-count bottles |
Primary outcome
MMS Adherence (amount) as assessed by number of MMS tablets consumed
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The number of MMS tablets (from a total possible 180 tablets) a pregnant woman consumes (sample 1).
MMS Adherence (frequency) as assessed by the frequency of tablets consumed
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The frequency of which MMS tablets are consumed by a pregnant woman. (sample group 1)
ANC Adherence as assessed by the number of ANC visits throughout pregnancy
Time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit
The number of ANC visits (from a total possible of 8 visits) a pregnant woman makes throughout her pregnancy (sample 1)
3 secondary outcomes
Proportion of pregnant women who indicate MMS Acceptability
Time frame: 3-month post-enrolment visit, 6-month post-enrolment visit, 6-week postpartum visit
MMS Acceptability among Health Providers assessed by focus group discussions
Time frame: 6 months, 12 months
Fidelity of providing MMS among Health Providers as assessed by focus group discussions
Time frame: 3-months, 6-months, 9-months, and 12-months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Sep 2026.
- Individual participant dataSharing planned: No
Related trials for Nutrient Deficiency
Enrolling by invitation
PROmega Pilot Study of Clinic-based DHA Blood Screening in Early Pregnancy
Nutrient Deficiency
RecruitingObservational study
Early Life Malnutrition, Environmental Enteric Dysfunction and Microbiome Trajectories
Malnutrition Pregnancy, Malnutrition in Children
Recruiting
Conversion to SADI-S, RYGB or OAGB After Failed Sleeve
Weight Loss, Bariatric Surgery Candidate
Enrolling by invitationObservational study
Challenges in Achieving Adequate Dietary Status of Women
Nutritional Status, Nutrient Deficiency
Active, not recruitingObservational study
Iodine Impact on Thyroid Function and Psychomotor Development, Observational Study in the Portuguese Minho Region
Iodine Deficiency, Thyroid
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Monica Fox, MHS principal investigator
Johns Hopkins University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Multiple Micronutrient Supplement (MMS) - dispensed in six 30-count bottles, Multiple Micronutrient Supplement (MMS) - dispensed in one 180-count bottle and Multiple Micronutrient Supplement (MMS) - dispensed in two 90-count bottles in people with Nutrient Deficiency, run by Johns Hopkins Bloomberg School of Public Health at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 24 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Harriet Babikako, PhD (256-0704-584-089, babikako@yahoo.com), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
MMS Adherence (amount) as assessed by number of MMS tablets consumed (time frame: 3-month post-enrolment, 6-month post-enrolment visit, 6-week postpartum visit). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Sep 2026.